XASX
CYP
Market cap2mUSD
Jul 10, Last price
0.01AUD
1D
-7.14%
1Q
-95.59%
Jan 2017
-98.22%
IPO
-99.70%
Name
Cynata Therapeutics Ltd
Chart & Performance
P/E
—
P/S
1.68
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.35%
Rev. gr., 5y
-23.10%
Revenues
2m
-18.59%
Net income
-9m
L-3.63%
CFO
-9m
L-12.45%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cynata Therapeutics Limited, an Australian biotechnology company headquartered in Cremorne, specializes in developing and bringing to market its unique Cymerus™ mesenchymal stem cell (MSC) technology for a wide array of human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully completed Phase I clinical trials addressing graft-versus-host disease (GvHD). Beyond this, its development pipeline features CYP-004, currently in Phase III clinical trials for osteoarthritis, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. The company is also actively investigating treatments for numerous other medical conditions, including asthma, myocardial infarction (heart attack), coronary artery disease, acute respiratory distress syndrome (ARDS), brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis (IPF), and opportunities in renal transplantation. Crucially, Cynata has forged a strategic partnership with Fujifilm, which provides essential clinical and commercial manufacturing and supply services for its Cymerus-based therapeutic MSC products. Originally incorporated in 2003 as Eco Quest Limited, the company rebranded as Cynata Therapeutics Limited in October 2013.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||